Cancer / Immunology

Optellum, Coreline Soft Join Forces to Build Integrated AI Pathway for Lung Nodule Care

Proposed collaboration would make Coreline Soft's FDA-cleared lung nodule detection capability available through Optellum's LungOS® platform &nbs...

 August 17, 2026 | News

China Accepts Laekna’s NDA for Afuresertib in Advanced Breast Cancer

Laekna (2105.HK) announced that the New Drug Application (NDA) for LAE002 (afuresertib) has been accepted by the Center for Drug Evaluation (CDE) of China'...

 August 13, 2026 | News

HanchorBio Partners with Taiwan Cancer Moonshot Team to Advance Precision Immunotherapy

Collaboration connects internationally recognized cancer multi-omics research with HanchorBio's clinical-stage immuno-oncology platform to accelerate bioma...

 August 11, 2026 | News

Akeso Doses First Patient in Phase II Trial of AK146D1–Ivonescimab Combination for Advanced Breast Cancer

Akeso, Inc. (9926.HK) ("Akeso" or the "Company")  announced that the first patient has been dosed in a Phase II clinical study (AK146D1-202) eval...

 August 11, 2026 | News

Innovent Doses First Patient in Phase 3 Trial of IBI363 for Advanced Colorectal Cancer

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

 August 07, 2026 | News

Kelun-Biotech's TROP2 ADC sac-TMT Advances Toward First-Line TNBC Approval in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application of its trophoblas...

 August 03, 2026 | News

IMPACT Therapeutics Partners with Pharmanovia to Commercialise Senaparib Across Europe, MENA, Australia and New Zealand

IMPACT Therapeutics ("IMPACT") (07630.HK) is pleased to announce that it has entered into an exclusive partnership (the "Exclusive Partnership") with Pharm...

 August 03, 2026 | News

Insilico Medicine's AI-Designed Cancer Drug Secures FDA Fast Track Status

FDA Fast Track Designation (FTD) aims to accelerate the review process of high-value assets, and ISM6331 marks Insilico's first FTD, recognizing the...

 July 31, 2026 | News

Ractigen Therapeutics Raises Over $31 Million to Advance saRNA Drug Pipeline

Ractigen Therapeutics, a clinical-stage biotechnology company pioneering small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery syste...

 July 31, 2026 | News

AbbVie Launches ELAHERE in Singapore for FRα-Positive Platinum-Resistant Ovarian Cancer

ELAHERE is the first and only antibody-drug conjugate (ADC) therapy approved specifically for patients with folate receptor alpha (FRα) positive,&n...

 July 29, 2026 | News

Harbour BioMed and Sinopharm Form Strategic Alliance to Accelerate Innovative Biologics

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

 July 29, 2026 | News

Kelun-Biotech Advances First Dual-Payload ADC into Clinical Trials for Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that it has received a clinical trial notice from t...

 July 29, 2026 | News

Seegene Advances Comprehensive HPV and STI PCR Testing with Large-Scale Clinical Evidence

STAgora™ analysis of approximately 60,000 test results collected over 42 months showed that STI pathogens were detected in 82% of HPV-positive case...

 July 29, 2026 | News

Telix Doses First Patient in Phase 3 Trial of TLX250-Tx for Kidney Cancer

•  First patient dosed in Phase 3 LUTEON[1] trial evaluating TLX250-Tx in relapsed or recurrent clear cell renal cell carcinoma (ccRCC).&bul...

 July 22, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close